Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

PHASE3CompletedINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

July 3, 2024

Study Completion Date

July 3, 2024

Conditions

Severe Aplastic Anemia

Interventions

DRUG

Hetrombopag Olamine+Standard Therapy

once daily

DRUG

Placebo+Standard Therapy

once daily

Trial Locations (1)

Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03825744 - Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia | Biotech Hunter | Biotech Hunter